CTOs on the Move

Total Life Changes

www.totallifechanges.com

 
Total Life Changes (TLC) is a debt-free company run by an experienced group of network marketing veterans. Jack Fallon (TLC CEO) has made it possible for people all over the world to improve their health and make money easily. TLC has a significant presence in over 140 countries, including the United States, Canada, Malaysia, India, and Indonesia.
  • Number of Employees: 1K-5K
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Omada Health

We`ve pioneered digital behavioral medicine: a new approach to tackling the growing epidemic of type 2 diabetes, heart disease, and obesity. Our online programs combine world-class science, technology, and design to inspire and enable people everywhere to live free of chronic disease. Named one of Fast Company`s “50 Most Innovative Companies in the World,” our team includes passionate and talented individuals from Google, IDEO, Harvard, Stanford, and Columbia. Our approach has been embraced by major employers across the country, including Costco and Iron Mountain, as well as leading health plans, such as Kaiser Permanente and Humana.

Embr Labs

Founded at MIT, the Embr Wave® & Wave 2 are personal cooling bands and heated wearables for fast, natural thermal wellness and thermotherapy.

Senior Concepts

Senior Concepts, Inc. is a Fort Worth, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Horizon Orthopedic

Horizon Orthopedic is a Brook Park, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Alector

Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel therapeutics for Alzheimer`s disease, other forms of dementia, and mechanistically related neurodegenerative disorders. Alector`s strategy is to efficiently generate and validate antibody drugs with unique functional properties that engage key disease-altering targets. This approach is enabled by a strategic alliance with Adimab, the industry leader in discovery and optimization of antibody therapeutics. Alector is currently developing leads for 4 major targets and anticipates taking 2 of these through pre-clinical development and IND enabling studies within 24 months. Alector has incorporated a highly integrated and lean biotechnology structure with extensive outsourcing that supports core scientific and management teams.